TCTMD
@tctmd.bsky.social
Your source for breaking news, topical videos, and slides covering cardiovascular disease and interventions. Register at http://tctmd.com
Prasugrel May Be Better Than Ticagrelor After PCI for Diabetes Patients With MVD
Prasugrel May Be Better Than Ticagrelor After PCI for Diabetes Patients With MVD
Prasugrel May Be Better Than Ticagrelor After PCI for Diabetes Patients With MVD
cmacahilig@crf.org
Thu, 11/13/2025 - 16:21
Todd Neale
In TUXEDO-2, ticagrelor failed to meet the bar for noninferiority, with most outcomes hinting at an advantage for prasugrel.
www.tctmd.com
November 13, 2025 at 9:30 PM
Prasugrel May Be Better Than Ticagrelor After PCI for Diabetes Patients With MVD
Déjà Vu All Over Again? Results of Intracoronary Stem Cell Study Questioned
Déjà Vu All Over Again? Results of Intracoronary Stem Cell Study Questioned
Déjà Vu All Over Again? Results of Intracoronary Stem Cell Study Questioned
cmacahilig@crf.org
Thu, 11/13/2025 - 14:14
Yael L. Maxwell
The BMJ cited several issues with the PREVENT-TAHA8 study data, concluding that the “results may not be reliable.”
www.tctmd.com
November 13, 2025 at 7:19 PM
Déjà Vu All Over Again? Results of Intracoronary Stem Cell Study Questioned
Artificial Intelligence Successfully Adjudicates Clinical Events in CV Trials
Artificial Intelligence Successfully Adjudicates Clinical Events in CV Trials
Artificial Intelligence Successfully Adjudicates Clinical Events in CV Trials
cmacahilig@crf.org
Thu, 11/13/2025 - 14:00
Yael L. Maxwell
The hope is using AI to judge outcomes will ease the high cost and complexity of running big clinical trials, say researchers.
www.tctmd.com
November 13, 2025 at 7:10 PM
Artificial Intelligence Successfully Adjudicates Clinical Events in CV Trials
DOACs may have fewer adverse events than DAPT after left atrial appendage closure, making it a safer option, according to data from the ANDES trial presented at #TCT2025. Read more here: www.tctmd.com/news/doac-ma...
DOAC May Be Safer Than DAPT After Left Atrial Appendage Closure: ANDES
The trial showed no difference in device-related thrombosis, but there were fewer adverse events with DOACs.
www.tctmd.com
November 13, 2025 at 3:54 PM
DOACs may have fewer adverse events than DAPT after left atrial appendage closure, making it a safer option, according to data from the ANDES trial presented at #TCT2025. Read more here: www.tctmd.com/news/doac-ma...
DARE-AF Dapagliflozin Fails to Reduce AF Burden After Catheter Ablation
DARE-AF Dapagliflozin Fails to Reduce AF Burden After Catheter Ablation
DARE-AF Dapagliflozin Fails to Reduce AF Burden After Catheter Ablation
cmacahilig@crf.org
Wed, 11/12/2025 - 14:52
Todd Neale
Clyde Yancy emphasized that, instead, “there is a benefit to lifestyle modification” in AF.
www.tctmd.com
November 12, 2025 at 8:00 PM
DARE-AF Dapagliflozin Fails to Reduce AF Burden After Catheter Ablation
On this episode of Talking Points, @mmamas1973.bsky.social, Philippe Généreux, Nicolas Van Mieghem, and Bernard Prendergast discuss the EARLY TAVR and TAVR UNLOAD trials. Listen now: www.tctmd.com/audio/early-...
November 12, 2025 at 7:02 PM
On this episode of Talking Points, @mmamas1973.bsky.social, Philippe Généreux, Nicolas Van Mieghem, and Bernard Prendergast discuss the EARLY TAVR and TAVR UNLOAD trials. Listen now: www.tctmd.com/audio/early-...
Lower Mortality With Complete Revascularization in Acute MI Patients with MVD
Lower Mortality With Complete Revascularization in Acute MI Patients with MVD
Lower Mortality With Complete Revascularization in Acute MI Patients with MVD
cmacahilig@crf.org
Wed, 11/12/2025 - 13:34
Michael O'Riordan
The patient-level meta-analysis takes the existing evidence to the next level, says Shamir Mehta.
www.tctmd.com
November 12, 2025 at 6:44 PM
Lower Mortality With Complete Revascularization in Acute MI Patients with MVD
Beta-blockers Not Helpful After MI in Patients With Preserved EF
Beta-blockers Not Helpful After MI in Patients With Preserved EF
Beta-blockers Not Helpful After MI in Patients With Preserved EF
cmacahilig@crf.org
Wed, 11/12/2025 - 13:21
Yael L. Maxwell
The meta-analysis confirms the need to update guidelines and change long-held practice patterns, experts say.
www.tctmd.com
November 12, 2025 at 6:30 PM
Beta-blockers Not Helpful After MI in Patients With Preserved EF
For the detection of angiographically confirmed STEMI, AI-ECG outperformed standard processes, slashing false-positive cath lab activations, according to a retrospective study. More here:
#TCT2025 www.tctmd.com/news/ai-ecg-...
#TCT2025 www.tctmd.com/news/ai-ecg-...
AI-ECG Finds STEMI Faster, Cuts False-Positive Cath Lab Activations
Physicians will remain in the loop, but AI can “turbocharge and augment our abilities,” an emergency medicine physician says.
www.tctmd.com
November 12, 2025 at 4:41 PM
For the detection of angiographically confirmed STEMI, AI-ECG outperformed standard processes, slashing false-positive cath lab activations, according to a retrospective study. More here:
#TCT2025 www.tctmd.com/news/ai-ecg-...
#TCT2025 www.tctmd.com/news/ai-ecg-...
The EARLY TAVR and TAVR UNLOAD Trials
The EARLY TAVR and TAVR UNLOAD Trials
The EARLY TAVR and TAVR UNLOAD Trials
cmacahilig@crf.org
Wed, 11/12/2025 - 09:53
56 seconds ago
For patients with aortic stenosis, is earlier intervention beneficial? Mamas Mamas, Philippe Généreux, Nicolas Van Mieghem, and Bernard Prendergast discuss.
www.tctmd.com
November 12, 2025 at 2:58 PM
The EARLY TAVR and TAVR UNLOAD Trials
CELEBRATE: Zalunfiban, a Novel Glycoprotein IIb/IIIa Inhibitor, Helps in STEMI
CELEBRATE: Zalunfiban, a Novel Glycoprotein IIb/IIIa Inhibitor, Helps in STEMI
CELEBRATE: Zalunfiban, a Novel Glycoprotein IIb/IIIa Inhibitor, Helps in STEMI
cmacahilig@crf.org
Tue, 11/11/2025 - 11:34
Michael O'Riordan
The drug, delivered by EMS as a single injection, improved infarct-related patency at cath lab arrival and 30-day clinical outcomes.
www.tctmd.com
November 11, 2025 at 4:42 PM
CELEBRATE: Zalunfiban, a Novel Glycoprotein IIb/IIIa Inhibitor, Helps in STEMI
Using a novel “unlocking” coronary device may reduce the risk of target lesion failure between 6 months and 2 years by nearly 50%, based on an analysis from the INFINITY-SWEDEHEART trial presented at this year's #TCT2025. www.tctmd.com/news/infinit...
INFINITY-SWEDEHEART: ‘Unlocking’ Device Bests DES Over Time
Bioadaptor was designed to restore normal vessel function and reduce late stent-related complications. It’s working so far.
www.tctmd.com
November 11, 2025 at 3:04 PM
Using a novel “unlocking” coronary device may reduce the risk of target lesion failure between 6 months and 2 years by nearly 50%, based on an analysis from the INFINITY-SWEDEHEART trial presented at this year's #TCT2025. www.tctmd.com/news/infinit...
Liberal Transfusion Doesn’t Decrease MACE in Surgery Patients at High Cardiac Risk: TOP
Liberal Transfusion Doesn’t Decrease MACE in Surgery Patients at High Cardiac Risk: TOP
Liberal Transfusion Doesn’t Decrease MACE in Surgery Patients at High Cardiac Risk: TOP
cmacahilig@crf.org
Mon, 11/10/2025 - 14:02
Caitlin E. Cox
Mortality/major ischemic events at 90 days were no lower than with a restrictive strategy—but cardiac complications differed.
www.tctmd.com
November 10, 2025 at 7:15 PM
Liberal Transfusion Doesn’t Decrease MACE in Surgery Patients at High Cardiac Risk: TOP
AI-Powered Digital Stethoscope Detects Low EF in Patients With HF Symptoms
AI-Powered Digital Stethoscope Detects Low EF in Patients With HF Symptoms
AI-Powered Digital Stethoscope Detects Low EF in Patients With HF Symptoms
cmacahilig@crf.org
Mon, 11/10/2025 - 13:13
Todd Neale
The device may help boost early detection of HFrEF for people living in low-resource settings where echo is scarce.
www.tctmd.com
November 10, 2025 at 6:21 PM
AI-Powered Digital Stethoscope Detects Low EF in Patients With HF Symptoms
Fish Oil Halves CV Risk in Patients on Dialysis: PISCES
Fish Oil Halves CV Risk in Patients on Dialysis: PISCES
Fish Oil Halves CV Risk in Patients on Dialysis: PISCES
cmacahilig@crf.org
Mon, 11/10/2025 - 11:34
Yael L. Maxwell
With such a large reduction, coupled with general skepticism around PUFAs, experts would like to see the trial replicated.
www.tctmd.com
November 10, 2025 at 4:42 PM
Fish Oil Halves CV Risk in Patients on Dialysis: PISCES
Oral PCSK9 Inhibitor Enlicitide Cuts LDL Cholesterol: CORALreef Lipids
Oral PCSK9 Inhibitor Enlicitide Cuts LDL Cholesterol: CORALreef Lipids
Oral PCSK9 Inhibitor Enlicitide Cuts LDL Cholesterol: CORALreef Lipids
cmacahilig@crf.org
Mon, 11/10/2025 - 10:56
Michael O'Riordan
An oral agent is needed because some patients don’t like injectables, and some doctors don’t prescribe them, experts say.
www.tctmd.com
November 10, 2025 at 4:24 PM
Oral PCSK9 Inhibitor Enlicitide Cuts LDL Cholesterol: CORALreef Lipids
Performing PCI to open up the graft for patients with failed SVGs after CABG reduces the rate of major CV events compared with intervening on the bypassed native coronary artery, according to results from the PROCTOR trial. #TCT2025 www.tctmd.com/news/proctor...
PROCTOR: PCI of Failed Bypass Grafts Tops Native-Vessel PCI, With Caveats
The saphenous vein grafts treated in the RCT were relatively straightforward, while the native vessels were largely CTOs.
www.tctmd.com
November 10, 2025 at 2:57 PM
Performing PCI to open up the graft for patients with failed SVGs after CABG reduces the rate of major CV events compared with intervening on the bypassed native coronary artery, according to results from the PROCTOR trial. #TCT2025 www.tctmd.com/news/proctor...
LAAO Doesn’t Match Medical Therapy for High-risk AF Patients: CLOSURE-AF
LAAO Doesn’t Match Medical Therapy for High-risk AF Patients: CLOSURE-AF
LAAO Doesn’t Match Medical Therapy for High-risk AF Patients: CLOSURE-AF
ccox@crf.org
Sun, 11/09/2025 - 15:54
Caitlin E. Cox
The noninferiority trial of patients at risk for both bleeding and stroke, in a surprise turn, found standard care to be superior.
www.tctmd.com
November 9, 2025 at 9:03 PM
LAAO Doesn’t Match Medical Therapy for High-risk AF Patients: CLOSURE-AF
DECAF: Daily Coffee, Not Abstinence, Beneficial for AF Patients
DECAF: Daily Coffee, Not Abstinence, Beneficial for AF Patients
DECAF: Daily Coffee, Not Abstinence, Beneficial for AF Patients
ccox@crf.org
Sun, 11/09/2025 - 15:28
Michael O'Riordan
In patients with persistent AF who underwent cardioversion, a cup of joe per day lowered the risk of recurrences at 6 months.
www.tctmd.com
November 9, 2025 at 8:36 PM
DECAF: Daily Coffee, Not Abstinence, Beneficial for AF Patients
Anticoagulation Alone Is Best in AF Patients a Year or More Out From PCI
Anticoagulation Alone Is Best in AF Patients a Year or More Out From PCI
Anticoagulation Alone Is Best in AF Patients a Year or More Out From PCI
ccox@crf.org
Sun, 11/09/2025 - 12:28
Todd Neale
In ADAPT AF-DES, adding clopidogrel in the chronic phase of coronary disease had no ischemic benefit and increased bleeding.
www.tctmd.com
November 9, 2025 at 5:36 PM
Anticoagulation Alone Is Best in AF Patients a Year or More Out From PCI
Three-year data from the LIFE-BTK trial shows that a drug-eluting resorbable scaffold continues to keep many patients with below-the-knee chronic limb-threatening ischemia free from repeat procedures even after it dissolves. #TCT2025 www.tctmd.com/news/life-bt...
LIFE-BTK: 3-Year Data Keep Dissolving Scaffold’s Durability Hopes Alive in CLTI
The everolimus scaffold, which had mostly disappeared by 3 years, was still associated with fewer reinterventions than PTA.
www.tctmd.com
November 9, 2025 at 3:03 PM
Three-year data from the LIFE-BTK trial shows that a drug-eluting resorbable scaffold continues to keep many patients with below-the-knee chronic limb-threatening ischemia free from repeat procedures even after it dissolves. #TCT2025 www.tctmd.com/news/life-bt...
Stopping DOACs After Successful AF Ablation Feasible in Low-risk Patients: OCEAN
Stopping DOACs After Successful AF Ablation Feasible in Low-risk Patients: OCEAN
Stopping DOACs After Successful AF Ablation Feasible in Low-risk Patients: OCEAN
ccox@crf.org
Sat, 11/08/2025 - 18:00
Michael O'Riordan
All experts warned that the trial results don’t apply to higher-risk groups.
www.tctmd.com
November 8, 2025 at 11:09 PM
Stopping DOACs After Successful AF Ablation Feasible in Low-risk Patients: OCEAN
One Month of Dual Antithrombotic Therapy May Be Enough After PCI in AF Patients
One Month of Dual Antithrombotic Therapy May Be Enough After PCI in AF Patients
One Month of Dual Antithrombotic Therapy May Be Enough After PCI in AF Patients
ccox@crf.org
Sat, 11/08/2025 - 17:37
Todd Neale
A caveat to the OPTIMA-AF trial: event rates were much lower than expected, complicating interpretation.
www.tctmd.com
November 8, 2025 at 10:46 PM
One Month of Dual Antithrombotic Therapy May Be Enough After PCI in AF Patients
Triple Agonist Appears Promising for Patients With Severe Hypertriglyceridemia
Triple Agonist Appears Promising for Patients With Severe Hypertriglyceridemia
Triple Agonist Appears Promising for Patients With Severe Hypertriglyceridemia
ccox@crf.org
Sat, 11/08/2025 - 12:58
Caitlin E. Cox
The drug, given as a weekly subcutaneous injection, reduced both triglycerides and liver fat in the phase II trial.
www.tctmd.com
November 8, 2025 at 6:12 PM
Triple Agonist Appears Promising for Patients With Severe Hypertriglyceridemia
Evolocumab Cuts MACE Risk in Patients Without Prior MI, Stroke: VESALIUS-CV
Evolocumab Cuts MACE Risk in Patients Without Prior MI, Stroke: VESALIUS-CV
Evolocumab Cuts MACE Risk in Patients Without Prior MI, Stroke: VESALIUS-CV
ccox@crf.org
Sat, 11/08/2025 - 10:11
Michael O'Riordan
It’s the first study to show a PCSK9 inhibitor can reduce major events in high-risk patients who haven’t yet had one.
www.tctmd.com
November 8, 2025 at 3:17 PM
Evolocumab Cuts MACE Risk in Patients Without Prior MI, Stroke: VESALIUS-CV